Skip to main content
Premium Trial:

Request an Annual Quote

OGT, Mergen Settle Microarray Patent-Infringement Suit

NEW YORK, Jan. 20 (GenomeWeb News) - Mergen and Oxford Gene Technology agreed on Jan. 13 to settle the patent-infringement litigation between them, according to Mergen spokesperson Jamie Love.

Under the terms of the deal, Sunnyvale, Calif.-based Mergen has purchased a license from Oxford, UK-based OGT allowing the company to manufacture and sell microarrays for investigating gene expression. Mergen has also dropped a countersuit as part of the deal.

Mergen spokesperson Love declined to disclose financial terms of the agreement.

Mergen sells the ExpressChip microarray.

The suit was one of several that OGT filed in the US District Court for the Northern District of Illinois in December 2002 to protect its broad US patent covering oligonucleotide arrays, according to GenomeWeb News' sister publication BioArray News.

Oxford Gene Technology manages the IP of microarray pioneer Edwin Southern, who jointly owns the patents with OxfordUniversity 

In mid-June, the company settled a similar suit it had filed in the same court, at the same time, against Motorola. That suit concerned Motorola's eSensor DNA Detection System.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.